<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPJ</journal-id>
<journal-id journal-id-type="hwp">spcpj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Pediatr (Phila)</journal-id>
<journal-title>Clinical Pediatrics</journal-title>
<issn pub-type="ppub">0009-9228</issn>
<issn pub-type="epub">1938-2707</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0009922811405519</article-id>
<article-id pub-id-type="publisher-id">10.1177_0009922811405519</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Premature Neonate With Leukocytosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Moreira</surname><given-names>Alvaro</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922811405519">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rouce</surname><given-names>Rayne</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922811405519">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Richardson</surname><given-names>C. Joan</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922811405519">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jain</surname><given-names>Sunil</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922811405519">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0009922811405519"><label>1</label>University of Texas Medical Branch at Galveston, Galveston, TX, USA</aff>
<author-notes>
<corresp id="corresp1-0009922811405519">Alvaro Moreira, University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, TX 77550, USA Email: <email>agmoreir@utmb.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>51</volume>
<issue>7</issue>
<fpage>692</fpage>
<lpage>693</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<sec id="section1-0009922811405519">
<title>Case Report</title>
<p>A 35-week preterm female, weighing 1850 g, is born to a gravida 4, para 4, 38-year-old mother by Cesarean section for fetal intolerance to labor. The pregnancy was complicated by an abnormal triple screen; however, amniocentesis was declined. Maternal hepatitis surface antigen, human immunodeficiency virus, and rapid plasma regain, and group B streptococci were negative. Membranes were ruptured artificially at delivery with clear fluid and Apgar scores of 8 and 8 at 1 and 5 minutes, respectively. The infant was transferred to neonatal intensive care unit for further care.</p>
</sec>
<sec id="section2-0009922811405519">
<title>Physical Examination</title>
<p>On presentation to the unit, the patient was in respiratory distress; her respiratory rate was 60 to 70 breaths per minute, heart rate 155 beats per minute, temperature 97.8°F, and oxygen saturation of 94% on nasal continuous positive airway pressure (NCPAP) of 5 cm of H<sub>2</sub>O and FiO<sub>2</sub> of 30%. On physical examination, the infant had a soft, large anterior fontanelle and upward slanting palpebral fissures. The nares were patent bilaterally with nasal prongs in place; she also had a large tongue and low set ears. The lungs had appropriate air entry with equal breath sounds and visible tachypnea with intercoastal retractions. Cardiac auscultation was unremarkable for murmurs, rubs, or gallops, but thoracic examination was significant for widely spaced nipples. Abdomen was soft, nondistended with positive bowel sounds, and the liver was palpated 4 cm below the coastal margin. Musculoskeletal exam was significant for hypotonia and clinodactyly to fifth digits.</p>
</sec>
<sec id="section3-0009922811405519">
<title>Pertinent Laboratory Values</title>
<p>The white blood cell count was 57.2 × 10<sup>3</sup>/µL, granulocyte 16%, bands 18%, lymphocyte 23%, monocyte 6%, and peripheral smear showed 33% blasts, hemoglobin 16.1 g/dL, hematocrit 49.1%, and platelets 633 × 10<sup>3</sup>/µL. Serum electrolytes, blood urea nitrogen, creatinine were all within the reference range for age. Unconjugated bilirubin was 14.9 mg/dL at 19 hours of life. Physical exam findings as well as karyotyping were consistent for trisomy 21. Cardiac echocardiogram was significant for small membranous ventricular septal defect.</p>
</sec>
<sec id="section4-0009922811405519">
<title>Hospital Course</title>
<p>The infant was treated for respiratory distress syndrome with several days of NCPAP and one dose of surfactant. The infant was placed on empiric antibiotics and discontinued once blood cultures were negative for 72 hours. She was started on total parenteral nutrition. Phototherapy was used for the first week of life. Repeat blood counts showed worsening leukocytosis and thrombocytosis. Pediatric hematology was consulted and recommended daily blood counts (<xref ref-type="fig" rid="fig1-0009922811405519">Figure 1</xref>).</p>
</sec>
<sec id="section5-0009922811405519">
<title>Final Diagnosis</title>
<p>Transient myeloproliferative disorder.</p>
</sec>
<sec id="section6-0009922811405519">
<title>Discussion</title>
<p>Trisomy 21, or Down syndrome, occurs in one of every 600 to 1000 live births in the United States.<sup><xref ref-type="bibr" rid="bibr1-0009922811405519">1</xref>,<xref ref-type="bibr" rid="bibr2-0009922811405519">2</xref></sup> In addition to having cardiac, endocrine, neurologic, and musculoskeletal involvement, children with Down syndrome are at increased risk for various hematologic disorders.<sup><xref ref-type="bibr" rid="bibr3-0009922811405519">3</xref></sup> Transient myeloproliferative disorder (TMD), also known as transient leukemia, is a hematologic abnormality that occurs in up to 10% of newborns with trisomy 21.<sup><xref ref-type="bibr" rid="bibr4-0009922811405519">4</xref></sup> Although this condition is rare, knowing how these patients present and its possible complications is significant when caring for infants with trisomy 21.</p>
<p>TMD can have different presentations in newborns but usually includes leukocytosis with increased blast cells.<sup><xref ref-type="bibr" rid="bibr5-0009922811405519">5</xref></sup> Transient leukemia is usually considered a benign condition since it spontaneously resolves within the first 3 months of life. However, there is a 400 to 500 times greater risk for infants with TMD to go on to develop acute megakaryoblastic leukemia (AMKL) before school age.<sup><xref ref-type="bibr" rid="bibr6-0009922811405519">6</xref></sup> In addition, 20% of the time it can manifest with multi-organ involvement, including hepatosplenomegaly, hyperbilirubinemia, liver failure, pericardial effusion, ascites, pulmonary edema, and even hydrops fetalis.<sup><xref ref-type="bibr" rid="bibr7-0009922811405519">7</xref></sup></p>
<p>The exact pathogenesis of TMD remains a mystery, although recent studies have found a link between blast cells from patients with trisomy 21 who develop TMD and mutations in the transcription factor (<italic>GATA1</italic>), which controls erythropoiesis.<sup><xref ref-type="bibr" rid="bibr6-0009922811405519">6</xref></sup> Ahmed et al has also found that <italic>GATA1</italic> mutations have been observed in both TMD and AMKL.<sup><xref ref-type="bibr" rid="bibr8-0009922811405519">8</xref></sup> Furthermore, samples of patients with trisomy 21 who developed AMKL do not have measurable <italic>GATA1</italic> abnormalities once their cells have been treated and are now in remission. Research has also shown that TMD has been connected to a small number of patients who do not have trisomy 21.<sup><xref ref-type="bibr" rid="bibr9-0009922811405519">9</xref></sup></p>
<p>Although peripheral blood samples are most helpful in diagnosing TMD, one can only truly diagnose the disorder once time reveals normalization of blast cell count. Most patients with transient leukemia can be managed with supportive care. However, patients with elevated liver enzymes, respiratory or cardiac failure, or those with white blood cell count &gt;100 000/mm<sup>3</sup> have shown improvement with chemotherapeutic agents, such as cytosine arabinoside.<sup><xref ref-type="bibr" rid="bibr9-0009922811405519">9</xref>,<xref ref-type="bibr" rid="bibr10-0009922811405519">10</xref></sup> When cytosine is given, it is usually administered for less than 1 week as infants with Down syndrome may be more susceptible to infectious agents.<sup><xref ref-type="bibr" rid="bibr11-0009922811405519">11</xref></sup> Fortunately, our patient had an improvement in her white blood cell counts by the second week of life (refer to <xref ref-type="fig" rid="fig1-0009922811405519">Figure 1</xref>).</p>
<fig id="fig1-0009922811405519" position="float">
<label>Figure 1.</label>
<caption>
<p>Hematologic findings in the patient with transient myeloproliferative disorder</p>
</caption>
<graphic xlink:href="10.1177_0009922811405519-fig1.tif"/>
</fig>
<p>In accordance with the American Academy of Pediatrics, physicians caring for newborns with Down syndrome should be aware that a complete blood count with manual differential within the first month of life is recommended.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0009922811405519">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henry</surname><given-names>E</given-names></name>
<name><surname>Walker</surname><given-names>D</given-names></name>
<name><surname>Wiedmeier</surname></name>
<name><surname>Christensen</surname><given-names>RD</given-names></name>
</person-group>. <article-title>Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system</article-title>. <source>Am J Med Genet A</source>. <year>2007</year>;<volume>143</volume>:<fpage>42</fpage>-<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr2-0009922811405519">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>G</given-names></name>
<name><surname>Nagano</surname><given-names>M</given-names></name>
<name><surname>Kanezaki</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Frequent mutations in the <italic>GATA-1</italic> gene in the transient myeloproliferative disorder of Down syndrome</article-title>. <source>Blood</source>. <year>2003</year>;<volume>102</volume>:<fpage>2960</fpage>-<lpage>2968</lpage>.</citation>
</ref>
<ref id="bibr3-0009922811405519">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kruger</surname><given-names>B</given-names></name>
</person-group>. <article-title>Transient myeloproliferative disorder associated with trisomy 21</article-title>. <source>Neonatal Netw</source>. <year>2007</year>;<volume>26</volume>:<fpage>7</fpage>-<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr4-0009922811405519">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rhoderick</surname><given-names>J</given-names></name>
<name><surname>Bradshaw</surname><given-names>W</given-names></name>
</person-group>. <article-title>Transient myeloproliferative disorder in a newborn with Down syndrome</article-title>. <source>Adv Neonatal Care</source>. <year>2008</year>;<volume>8</volume>:<fpage>208</fpage>-<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr5-0009922811405519">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roy</surname><given-names>A</given-names></name>
<name><surname>Roberts</surname><given-names>I</given-names></name>
<name><surname>Norton</surname><given-names>A</given-names></name>
<name><surname>Vyas</surname><given-names>P</given-names></name>
</person-group>. <article-title>Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis</article-title>. <source>Br J Haematol</source>. <year>2009</year>;<volume>147</volume>:<fpage>3</fpage>-<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr6-0009922811405519">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heald</surname><given-names>B</given-names></name>
<name><surname>Hilden</surname><given-names>J</given-names></name>
<name><surname>Zbuk</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Severe TMD/AMKL with <italic>GATA1</italic> mutation in a stillborn fetus with Down syndrome</article-title>. <source>Nat Clin Pract Oncol</source>. <year>2007</year>;<volume>4</volume>:<fpage>433</fpage>-<lpage>438</lpage>.</citation>
</ref>
<ref id="bibr7-0009922811405519">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirono</surname><given-names>K</given-names></name>
<name><surname>Miura</surname><given-names>M</given-names></name>
<name><surname>Kanegane</surname><given-names>H</given-names></name>
</person-group>. <article-title>Hepatocyte growth factor in transient myeloproliferative disorder of Down syndrome</article-title>. <source>Pediatr Int</source>. <year>2009</year>;<volume>51</volume>:<fpage>754</fpage>-<lpage>755</lpage>.</citation>
</ref>
<ref id="bibr8-0009922811405519">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>M</given-names></name>
<name><surname>Sternberg</surname><given-names>A</given-names></name>
<name><surname>Hall</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Natural history of <italic>GATA1</italic> mutations in Down syndrome</article-title>. <source>Blood</source>. <year>2004</year>;<volume>103</volume>:<fpage>2480</fpage>-<lpage>2489</lpage>.</citation>
</ref>
<ref id="bibr9-0009922811405519">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Apollonsky</surname><given-names>N</given-names></name>
<name><surname>Shende</surname><given-names>A</given-names></name>
<name><surname>Ouansafi</surname><given-names>I</given-names></name>
<name><surname>Brody</surname><given-names>J</given-names></name>
<name><surname>Atlas</surname><given-names>M</given-names></name>
<name><surname>Aygun</surname><given-names>B</given-names></name>
</person-group>. <article-title>Transient myeloproliferative disorder in neonates with and without Down syndrome: a tale of 2 syndromes</article-title>. <source>J Pediatr Hematol Oncol</source>. <year>2008</year>;<volume>30</volume>:<fpage>860</fpage>-<lpage>864</lpage>.</citation>
</ref>
<ref id="bibr10-0009922811405519">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hojo</surname><given-names>S</given-names></name>
<name><surname>Tsukimori</surname><given-names>K</given-names></name>
<name><surname>Kitade</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Prenatal sonographic findings and hematological abnormalities in fetuses with transient abnormal myelopoiesis with Down syndrome</article-title>. <source>Prenat Diagn</source>. <year>2007</year>;<volume>27</volume>:<fpage>507</fpage>-<lpage>511</lpage>.</citation>
</ref>
<ref id="bibr11-0009922811405519">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Craze</surname><given-names>JL</given-names></name>
<name><surname>Harrison</surname><given-names>G</given-names></name>
<name><surname>Wheatley</surname><given-names>K</given-names></name>
<name><surname>Hann</surname><given-names>IM</given-names></name>
<name><surname>Chessells</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Improved outcome of acute myeloid leukaemia in Down’s syndrome</article-title>. <source>Arch Dis Child</source>. <volume>81</volume>:<fpage>32</fpage>-<lpage>37</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>